AlphaStocks
4.0
Weak

REPLIGEN CORP (RGEN)

Health Care / Biotechnology

S&P MidCap 400

$118.34

Below average on several measures. Research carefully.

Weak

Score based on 5 of 5 models — high confidence

#842out of 1127 in Health Care

Is REPLIGEN CORP a Good Investment in 2026?

REPLIGEN CORP (RGEN) scores 4.0 out of 10 on AlphaStocks' composite model, earning a Weak rating. The Piotroski model rates REPLIGEN CORP as Strong (7/9). However, the Greenblatt Magic Formula model rates it Caution — Bottom half (rank 84%). REPLIGEN CORP ranks #842 out of 1127 stocks in the Health Care sector.

This summary is algorithmically generated and is not financial advice.

Key Metrics

P/E136.9ROE2.3Market Cap7B

Valuation

Trades at 137x earnings — significantly above sector median of 25x. Premium reflects market growth expectations.

Fair value estimate not available for this stock.

5-Model Analysis

Each model evaluates this stock from a different angle. Combined, they form the composite score above.

Piotroski

Strong

7/9

Buffett

Attractive

Business quality & competitive moat

Graham

Caution

Significantly above fair value

Lynch

Neutral

High PEG — growth premium · Slow Grower

Greenblatt

Caution

Bottom half (rank 84%)

Frequently Asked Questions

Is REPLIGEN CORP (RGEN) a good investment?
Based on AlphaStocks' composite analysis, REPLIGEN CORP (RGEN) scores 4.0 out of 10, earning a Weak rating. This score is below average, suggesting caution. Trades at 137x earnings — significantly above sector median of 25x. Premium reflects market growth expectations.
What is REPLIGEN CORP's Piotroski F-Score?
REPLIGEN CORP's Piotroski F-Score status is Strong. The raw score is 7/9. The Piotroski F-Score evaluates financial health using 9 fundamental signals including profitability, leverage, and operating efficiency.
Is RGEN overvalued or undervalued?
A precise fair value estimate is not available for RGEN. Trades at 137x earnings — significantly above sector median of 25x. Premium reflects market growth expectations.
How does RGEN compare to other Health Care stocks?
REPLIGEN CORP ranks #842 out of 1127 stocks in the Health Care sector, placing it in the top 75% of its sector by composite score. There are higher-ranked alternatives in this sector worth exploring.
What do investment models say about RGEN?
AlphaStocks evaluates RGEN using five proven investment models. Piotroski: Strong; Buffett: Attractive; Graham: Caution; Lynch: Neutral; Greenblatt Magic Formula: Caution. These models are combined into a single composite score of 4.0/10.

Similar Stocks

PARRFTIAZN

Compare RGEN with

RGEN vs PARRRGEN vs FTIRGEN vs AZN

Scores are algorithm-generated research tools, not investment recommendations. Past performance does not guarantee future results. Always do your own due diligence. Full disclaimer